Baroreflex

Physicians At St. David's Medical Center Among First In Nation To Implant Neurostimulator Technology For Advanced Heart Failure

Retrieved on: 
Monday, December 13, 2021
Heart rate, Blood, FDA, Patient, Elective surgery, Baroreflex, Criticism of the Food and Drug Administration, Nervous system, Saint David, Heart failure, Autonomic nervous system, Food, Brain, St Davids, Pressure, Thought, Quality of life, Medical Center, Blood vessel, Technology, Time-invariant system, Heart, Medical device, Medical imaging

AUSTIN, Texas, Dec. 13, 2021 /PRNewswire/ -- Doctors at St. David's Medical Center recently became among the first in the U.S. to implant a new neurostimulator technology to help treat advanced heart failure.

Key Points: 
  • AUSTIN, Texas, Dec. 13, 2021 /PRNewswire/ -- Doctors at St. David's Medical Center recently became among the first in the U.S. to implant a new neurostimulator technology to help treat advanced heart failure.
  • The Barostim System is the only technology approved by the Food and Drug Administration (FDA) to use the nervous system to control heart failure and improve the function of the cardiovascular system.
  • This triggers the baroreflex, the body's main cardiovascular reflex, causing an autonomic, or involuntary, response to the heart.
  • The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Physicians At St. David's Medical Center Among First In Nation To Implant Neurostimulator Technology For Advanced Heart Failure

Retrieved on: 
Monday, December 13, 2021
Nervous system, Heart, Patient, Blood, Thought, Baroreflex, Food, Heart failure, Blood vessel, FDA, Elective surgery, Pressure, Brain, Heart rate, Quality of life, Autonomic nervous system, Saint David, St Davids, Technology, Medical Center, Criticism of the Food and Drug Administration, Time-invariant system, Medical device, Medical imaging

AUSTIN, Texas, Dec. 13, 2021 /PRNewswire/ -- Doctors at St. David's Medical Center recently became among the first in the U.S. to implant a new neurostimulator technology to help treat advanced heart failure.

Key Points: 
  • AUSTIN, Texas, Dec. 13, 2021 /PRNewswire/ -- Doctors at St. David's Medical Center recently became among the first in the U.S. to implant a new neurostimulator technology to help treat advanced heart failure.
  • The Barostim System is the only technology approved by the Food and Drug Administration (FDA) to use the nervous system to control heart failure and improve the function of the cardiovascular system.
  • This triggers the baroreflex, the body's main cardiovascular reflex, causing an autonomic, or involuntary, response to the heart.
  • The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Total Brain Introduces Heart Rate Variability Measurement and Stress Management Tools

Retrieved on: 
Tuesday, October 19, 2021
ASX, HRV, TTB, Technology, Heart rate, Metabolic pathway, Resonance, Reproductive success, Root mean square, SAN, Exercise, Reading, Time, Mental health, Mindfulness, CEO, Fatigue, Brain, Breathing, Relaxation, Baroreflex, Blood, Science, Medical imaging

SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Total Brain , a mental health and brain performance self-monitoring and self-care platform, today announced the introduction of the Heart Rate Variability (HRV) Measurement to its robust, clinically-validated mobile platform.

Key Points: 
  • SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Total Brain , a mental health and brain performance self-monitoring and self-care platform, today announced the introduction of the Heart Rate Variability (HRV) Measurement to its robust, clinically-validated mobile platform.
  • HRV works in concert with Total Brain's Resonant Breathing exercise, offering real-time stress measurement and the ability to show the effectiveness of breathing exercises on stress levels.
  • "The introduction of Heart Rate Variability Measurement, coupled with Total Brain's Resonant Breathing exercise, reflects our commitment to leveraging the intersection of neuroscience and technology to continually enhance our product capabilities," noted Louis Gagnon, CEO, Total Brain.
  • Total Brain transforms the user's mobile phone's camera into an exceedingly accurate heart rate measurement device.

CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms

Retrieved on: 
Thursday, June 10, 2021
Branches of biology, Autonomic nervous system, Baroreflex, Blood pressure, Cardiovascular physiology, Human homeostasis, Reflexes, Neuromodulation, Baroreceptor, Therapy

The novel ultrasound-guided technique is the latest advancement of CVRxs Barostim Baroreflex Activation Therapy (BAT) to treat the symptoms of HF patients.

Key Points: 
  • The novel ultrasound-guided technique is the latest advancement of CVRxs Barostim Baroreflex Activation Therapy (BAT) to treat the symptoms of HF patients.
  • Commenting on the technology, Dr. Allred said, This new approach to treatment represents a potentially game-changing advancement in the way we manage patients with HF symptoms.
  • We are excited to participate in this study evaluating the ultrasound-guided approach as a new implant technique to deliver this therapy.
  • CVRx is dedicated to improving patient outcomes, quality of life, and overall cardiovascular health via novel baroreceptor neuromodulation therapies.

University of Chicago Researchers Conduct Study of Unique Device to Lower High Blood Pressure

Retrieved on: 
Tuesday, June 11, 2019
Health, Cardiology, Clinical trials, Medical devices, Research, Science, General Health, Branches of biology, Cardiovascular system, Circulatory system, Blood pressure, Sensory receptors, Cardiovascular physiology, Hypertension, Baroreceptor, Homeostasis, Artery, Baroreflex

This study, called CALM-2 (Controlling And Lowering blood pressure with MobiusHD), continues the study of the investigational MobiusHD device which was evaluated in an earlier proof-of-concept CALM-FIM which showed significant reductions in blood pressure through six months.

Key Points: 
  • This study, called CALM-2 (Controlling And Lowering blood pressure with MobiusHD), continues the study of the investigational MobiusHD device which was evaluated in an earlier proof-of-concept CALM-FIM which showed significant reductions in blood pressure through six months.
  • The new, larger, multi-center CALM-2 clinical trial has been designed to assess the safety and effectiveness of this unique device as a possible solution for patients whose blood pressure is not controlled with prescribed medications.
  • Specialized stretch-sensitive nerves called baroreceptors are located in the walls of the carotid arteries and play an essential role in the bodys natural blood pressure regulation.
  • Patients with high blood pressure who are non-responsive to multiple medications have very few treatment options, said Bakris.